OncoMatch/Clinical Trials/NCT07659639
Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic Cancer
Is NCT07659639 recruiting? Yes, currently enrolling (Jul 2026). This NA trial studies non-drug interventions for diabetes.
LASERBLOOD is based on a biophotonic technology that can be used to predict the development of Pancreatic Ductal Adenocarcinoma (PDAC) in particular categories of subjects at risk (e.g. persons with diabetes, obese people, patients with Intraductal Papillary Mucinous Neoplasm \[IPMN\] or other cystic diseases of the pancreas, etc.) and at the same time offer the possibility of verifying the real effectiveness of the treatments to which affected patients are subjected.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Lab requirements
Blood counts
no hematologic disorders
Kidney function
adequate renal function
Liver function
adequate hepatic function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07659639 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages